Anders Kronstrm - Infant Bacterial Chief Officer
| IBT-B Stock | SEK 39.40 0.60 1.55% |
Insider
Anders Kronstrm is Chief Officer of Infant Bacterial Therapeutics
| Age | 56 |
| Phone | 46 7 62 19 37 38 |
| Web | https://www.ibtherapeutics.com |
Infant Bacterial Management Efficiency
The company has return on total asset (ROA) of (0.1085) % which means that it has lost $0.1085 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.1801) %, meaning that it generated substantial loss on money invested by shareholders. Infant Bacterial's management efficiency ratios could be used to measure how well Infant Bacterial manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Mattis Ranthe | ExpreS2ion Biotech Holding | N/A | |
| Palle MS | Saniona AB | 65 | |
| Klaus Sindahl | Hansa Biopharma AB | N/A | |
| MBA MSc | Saniona AB | 63 | |
| Peter Nygren | Oncopeptides AB | 64 | |
| Katja Margell | Hansa Biopharma AB | N/A | |
| Jakob Lic | Oncopeptides AB | 51 | |
| Kristina Luthman | Oncopeptides AB | N/A | |
| Janus Larsen | Saniona AB | 51 | |
| Karin Nielsen | Saniona AB | N/A | |
| Anne Lanner | Hansa Biopharma AB | 54 | |
| Emanuel Bjrne | Hansa Biopharma AB | 50 | |
| MSc MD | Oncopeptides AB | N/A | |
| Bent MSc | ExpreS2ion Biotech Holding | N/A | |
| Linda Holmstrom | Oncopeptides AB | N/A | |
| Sren MSc | Hansa Biopharma AB | 58 | |
| Keith Alexander | ExpreS2ion Biotech Holding | N/A | |
| Lars Petersen | ExpreS2ion Biotech Holding | N/A | |
| Anita BCom | Saniona AB | 55 | |
| Pr MD | Oncopeptides AB | N/A | |
| MSc MSc | Oncopeptides AB | 53 | |
Management Performance
| Return On Equity | -0.18 | |||
| Return On Asset | -0.11 |
Infant Bacterial Leadership Team
Elected by the shareholders, the Infant Bacterial's board of directors comprises two types of representatives: Infant Bacterial inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Infant. The board's role is to monitor Infant Bacterial's management team and ensure that shareholders' interests are well served. Infant Bacterial's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Infant Bacterial's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Anders Kronstrm, Chief Officer | ||
| Maria Ekdahl, Chief Officer | ||
| Robert Molander, Chief Officer | ||
| Pr MD, Chief Officer | ||
| Staffan Stromberg, Chief Officer |
Infant Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Infant Bacterial a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.18 | |||
| Return On Asset | -0.11 | |||
| Current Valuation | 271.56 M | |||
| Shares Outstanding | 10.85 M | |||
| Shares Owned By Insiders | 7.23 % | |||
| Shares Owned By Institutions | 33.28 % | |||
| Price To Earning | (18.41) X | |||
| Price To Book | 1.72 X | |||
| Price To Sales | 8,324 X | |||
| Gross Profit | 12 K |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Infant Stock Analysis
When running Infant Bacterial's price analysis, check to measure Infant Bacterial's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Infant Bacterial is operating at the current time. Most of Infant Bacterial's value examination focuses on studying past and present price action to predict the probability of Infant Bacterial's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Infant Bacterial's price. Additionally, you may evaluate how the addition of Infant Bacterial to your portfolios can decrease your overall portfolio volatility.